PRESS RELEASE - FOR IMMEDIATE RELEASE

New York, NY – September 17, 2025 – Vibes AI is honored to join the UNFPA Equity 2030 Alliance, a global coalition committed to accelerating gender equity across science, technology, and innovation.

Our commitment: closing gender-equity gaps in the design and deployment of cognitive health technologies by centering women’s brain health in our research, product development, and investment priorities.

Through this initiative, Vibes AI will:

• Build and validate a women-centered voice biomarker database to improve early detection of cognitive and emotional health issues.
  
• Design personalized restorative audio programs tailored to women’s unique stress, sleep, and hormonal cycles.
  
• Publish open-access findings on sex-specific differences in voice-based indicators of cognitive load, burnout, and emotional regulation.
  
• Establish an advisory board that includes women scientists, clinicians, and community leaders to guide equitable research and product strategies.

Women represent nearly two-thirds of those living with Alzheimer’s and related dementias, yet their needs have historically been underrepresented in brain health research, product design, and investment. By embedding gender equity into the full lifecycle of our AI-powered brain health solutions, Vibes AI is creating technologies that reflect the unique neurological, hormonal, and cognitive health needs of women.

Together with UNFPA and global partners, we are shaping a future where women’s brain health is prioritized — advancing equity in science and improving cognitive wellness for all.

Learn more about the Equity 2030 Alliance.

About Vibes AI

Vibes AI is a neurotechnology company on a mission to accelerate the world's access to cognitive health & wellness. Founded in 2024, the company uses AI, neuroscience, and ancestral intelligence to create innovative solutions that make cognitive health and enhancement accessible to all. MANTRA, one of the company's flagship products, uses voice biomarker technology to detect early signs of cognitive decline and provide personalized interventions.